Trial Profile

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Apr 2026 According to an Immunocore media release, five-year overall survival (OS) was presented in an oral session at the American Association for Cancer Research (AACR) 2026 meeting.
20 Apr 2026 Results presented in an Immunocore Media Release.
18 Mar 2026 According to Immunocore media release, data from the trial will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting commencing on April 17, 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com